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Background: CD4+CD25+Foxp3+ regulatory T (Treg) cells inhibit autoimmunity and protect against tissue injury.
The development of these Treg cells is controlled by the regulator protein Foxp3, which can be enhanced by
the in vitro activation of Foxp3 in the presence of transforming growth factor-beta. However, little is known
about alternative methods, such as the use of natural products, for controlling Foxp3-mediated Treg cell
differentiation.
Method: HEK 293 T cells were transfected with Foxp3 expression plasmid, and then treated with different
compounds, Foxp3 mRNA expression was determined by real-time RT-PCR. CD4+CD25-T cells were stimulated
with Baicalin, Foxp3 protein expression were analyzed by flow cytometry and confocal microscopy, the
regulatory function of T cells stimulated with Baicalin was detected by the carboxyfluorescien succinimidyl
ester.
Results: We demonstrated that Baicalin, a compound isolated from the Chinese herb Huangqin, induced
Foxp3 protein expression in cultured T cells, promoted Treg cell differentiation and regulatory activity. Our data
also indicated that Baicalin restored Foxp3 expression following its initial interleukin-6-mediated inhibition and
induced Foxp3 expression in vitro.
Conclusions: These data suggest that Baicalin may promote Treg cell differentiation and regulatory activity
and may serve as a promising natural immunosuppressive compound for treating autoimmune inflammatory
diseases.
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CD4+CD25+Foxp3+ regulatory T (Treg) cells are essen-
tial for maintaining self-tolerance [1,2] and play key roles
in regulating immune system homeostasis [2]. Increasing
evidence suggests that Treg cells are capable of inhibiting
the function of Th1, Th2, Th17, and other effector cells;
inhibiting inflammation and preventing autoimmunity
[3,4]; therefore, the loss or dysfunction of Treg cells often
leads to autoimmune diseases such as systemic lupus
erythematosus [5] , type I diabetes and inflammatory bowel
disease [2,6]. The development and functions of Treg cells
are driven by the forkhead/winged-helix transcription factor
Foxp3 [7-9], whose important role in Treg cell activity was* Correspondence: li.ming@zs-hospital.sh.cn
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reproduction in any medium, provided the orpreviously demonstrated when mice expression mutant
Foxp3 exhibited impaired Treg cell activity and succumbed
to a fatal lymphoproliferative disorder, which was then
reversed by the transgenic expression of wild-type Foxp3 in
these animals [10].
Treg cells typically develop and proliferate in the thymus
upon contact with self-antigen and are then transported to
the peripheral immune system [2]. Several factors affecting
Treg cell homeostasis have been defined: for example, Treg
cell activity is interleukin (IL)-2-dependent [11]. In addition,
Treg cell activity can be induced in the peripheral immune
system by the conversion of naïve CD4+Foxp3- T cells into
Foxp3+ T cells by transforming growth factor-beta (TGF-β)
[4], which also maintains Foxp3 expression and can regulate
the functions of Treg cells [12]. Foxp3 is essential for the de-
velopment and function of CD4+CD25+ regulatory T cells
[13], induction of the transcription factor Foxp3 can con-
verse CD4+CD25- naïve T cells to CD4+CD25+ regulatory Td. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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amplifies the pre-established Treg cells [7]. The effect of
Foxp3 is to suppress the activation of target genes on T cell
stimulation, as well as inhibit the production of interleukin
(IL)-2, therefore Foxp3 is crucial for the normal function of
Treg cells [15]. Thus induction of Foxp3 expression and pro-
motion of Treg cells differentiation might be a promising
therapeutic method for the treatment of autoimmunity
diseases.
Recently, the vitamin A metabolite all-trans retinoic
acid was shown to enhance TGF-β-mediated induction
of Foxp3 [16-18]. In traditional Chinese medicine, some
herbs are used in various anti-inflammatory applications
[19-22], such as the treatment of autoimmune diseases,
by suppressing effector T-cell reactions [23]; however,
little is known about the role of natural compounds in
controlling the differentiation and functions of Treg cells.
Since Treg cells regulate the functions of effector T cells,
we hypothesized that some therapeutic herbs may sup-
press inflammation by promoting Foxp3-mediated Treg
cell differentiation and thus controlling effector T cell
activities. To support this, previous study showed that
berberine, an isoquinoline alkaloid derived from plants,
inhibited differentiation of Th17 cells and, to a lesser
degree, Th1 cells, whereas it had no effect on the relative
number of CD4+Foxp3+ regulatory T cells in the experi-
mental autoimmune encephalomyelitis mice [19]. Artemi-
sinin analog SM934 had therapeutic effects in lupus-prone
female MRL/lpr mice by inhibiting both Th1 cell and
Th17 cell responses, and elevated the percentage of Treg
cells ex vivo, but not Treg cells in vitro[22].
In this study, we selected herbs for the development of
Treg cells, two criteria are considered: the herb must be
safe for patient use, and the chemical structures of the ac-
tive ingredients of the herb must already be described. We
demonstrated that Baicalin, a flavonoid compound origin-
ally isolated from the Chinese herb Huangqin (Scutellaria
baicalensis Georgi), up-regulated Foxp3 mRNA expression
in HEK 293 T cells and promoted Treg cell differentiation.
Furthermore, we showed that Baicalin could restore Foxp3
expression following its initial IL-6-mediated inhibition,
Baicalin could also directly induce Foxp3 expression, pro-
mote Treg cell differentiation and regulatory activity. Our
findings indicate that Baicalin may be a promising naturalTable 1 The following primer pairs were used
Gene Forward (5'-3
Mus β-actin GACGGCCAGGTCATCA
Mus Foxp3 (239 T cell) CTACCCACTGCTGGCA
Mus Foxp3 (T cell) CCCAGGAAAGACAGC
Human 18S GCCCGAAGCGTTTACT
Human IL-6Rα CATTGCCATTGTTCTGAimmunosuppressive compound for treating inflammatory
diseases.Methods
Plasmids, cell lines, and transfection for Foxp3 mRNA
expression studies
The Foxp3-IRES-GFP expression plasmid (pZIGF) and con-
trol plasmid were kindly provided by Wang Shengjun. HEK
293 T cells (Chinese Academy of Sciences, Shanghai, China)
were maintained in Dulbecco’s modified Eagle’s medium
(Hyclone, Logan, UT) and transiently transfected with
pZIGF using Lipofectamine (Invitrogen, San Diego, CA). At
24 h post-transfection, HEK 293 T cells were treated with
different compounds (20 μM Baicalin, 10 μM Paeoniflorin,
0.5 ng/ml Triptolide, 1 μM Artemerher, 5 μM Cryptotan-
shinone, 30nM Retinoic acid, 10 μM Sinomenine, or 10 μM
Paeonol; All compounds are from National Institute for
the Control of Pharmaceutical and Biological Products,
Beijing, China) for another 24 h, and Foxp3 mRNA ex-
pression levels from cells in each group were determined
by real-time reverse transcription-polymerase chain reac-
tion (RT-PCR). For some experiments, HEK 293 T cells
were treated with different doses of Baicalin or incubated
with a constant dose of Baicalin (20 μM) for various treat-
ment times, and Foxp3 mRNA expression was analyzed by
real-time RT-PCR. Where indicated, cultures were supple-
mented with 5 ng/ml TGF-β, 20 ng/ml IL-6 (PeproTech,
Rocky Hill, NJ), 20 μM Baicalin, or DMSO vehicle control,
and Foxp3 mRNA expression was determined by RT-PCR.RNA isolation and real-time RT-PCR
Total RNA from transfected HEK 293 T cells was prepared
with the use of the Trizol reagent according to the manufac-
turer’s protocol (Invitrogen). cDNA was synthesized with a
first-strand cDNA synthesis kit and oligo (dT) primers
(Fermentas, Hanover, MD), and gene expression was exam-
ined with a Bio-Rad iCycler Optical System (Bio-Rad,
Richmond, CA) using a SYBR green real-time PCR Master
Mix (Toyobo, Osaka, Japan). The 2-ΔΔCt method was
used to normalize transcription levels to human 18S or
Mus β-actin and to calculate fold-changes in expression
levels relative to controls. The primer pairs could be seen






Figure 1 Screening of compounds that up-regulate Foxp3 expression. HEK 293 T cells were transfected with Foxp3 expression plasmids.
(A) Nuclear expression of Foxp3 in HEK 293 T cells was examined by immunofluorescence microscopy. Scale bar, 10 μm. (B) Foxp3 mRNA
expression in transfected HEK 293 T cells was determined by RT-PCR. (C) Twenty-four hours after transfection, cells were then treated with
different compounds for another 24 h. Foxp3 mRNA expression was analyzed by real-time RT-PCR. Data are expressed as mean± SD, and
compared with vector control (expression level of vector control was set as 1.0). Shown are results from three independent experiments.
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Wild-type C57BL/6 (B6) mice were purchased from the
Shanghai Laboratory Animal Center (Chinese Academy
of Sciences). The animal protocol was approved by the
Institutional Animal Use Committee of the Shanghai
Institutes for Biological Sciences. All mice were maintained
under pathogen-free conditions. Naïve CD4+CD25- T
(FITC-conjugated anti-CD4 and PE-conjugated anti-CD25,
eBioscience, San Diego, CA) cells from spleen of B6 mice
were isolated by fluorescence-activated cell sorting (FACS).
T cells were stimulated with 2 μg/ml plate-bound anti-CD3
and 2 μg/ml soluble anti-CD28 (eBioscience) for 3 days.
Where indicated, cultured Tcells were treated with differentdoses of Baicalin, and a DMSO-only control was used in
some experiments. For some experiments, CD4+CD25- T
cells were labeled by carboxyfluorescien succinimidyl ester
(CFSE, Invitrogen), and co-cultured with CD4+CD25+T
cells in the presence of 20 μM Baicalin for 5 days, the pro-
liferation of T cells was analyzed by flow cytometry.
Flow cytometry analysis and confocal microscopy
Cells obtained from in vitro cultures were first stained with
FITC-conjugated anti-CD4, PE-conjugated anti-CD25
(eBioscience). For Foxp3 staining, cells were treated with
PE-Cy5-conjugated anti-Foxp3 according to the manufac-
turer’s protocol (eBioscience). After staining, cells were
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using FlowJo software (Tree Star, San Carlos, CA). Cells
were then visualized with a Leica TCS SP2 confocal micro-
scope (Leica, Cambridge, UK), and fluorescence intensity
data were measured using LCS Lite software (Leica). Five
independent cells were selected randomly from each sample
for analysis.
Statistical analysis
Quantitative data were expressed as means ± standard
deviation (SD). The statistical significance was determined
by analysis of variance followed by a Bonferroni post-hoc
test for multiple comparisons or the Student’s t-test.
All p values ≤ 0.05 were considered significant.
Results
Screening of compounds up-regulating Foxp3 expression
To screen for natural compounds that up-regulate nuclear
transcription factor Foxp3 expression in T cells, HEK 293 T
cells were transiently transfected with the Foxp3-GFP ex-
pression plasmid pZIGF. Subsequent immunofluorescence
microscopy showed the nuclear localization of Foxp3 in
the cells (Figure 1A), which allowed us to accurately iden-
tify compounds that affect the gene expression of Foxp3.
Real-time RT-PCR confirmed that Foxp3 mRNA expressionFigure 2 Baicalin up-regulates Foxp3 expression in HEK 293 T cells. Fo
(A) Twenty-four hours after transfection, cells were treated with Baicalin for
expression is shown. Date are expressed as mean± SD and compared with
1.0). (B) After transfection with Foxp3 expression plasmids, a second group
induction of Foxp3 mRNA expression is shown. Data are expressed as mean
293 T cells were treated with indicated cytokines in the presence or absenc
(D) HEK 293 T cells were treated with IL-6 in the presence or absence of Balevels were higher in pZIGF-transfected HEK 293 T cells
when compared with vector-only control cells (Figure 1B).
To identify novel compounds that up-regulate Foxp3
expression, the transfected HEK 293 T cells were then trea-
ted with different anti-inflammatory compounds isolated
from Chinese herbs at concentrations that would not ad-
versely affect cell proliferation (data not shown). Among the
different compounds tested, Baicalin (7-glucuronic acid, 5,
6-dihydroxyflavone, molecular weight =446.36) induced the
highest expression of Foxp3 mRNA (Figure 1C). We
confirmed this finding by stimulating HEK 293 T cells with
combinations of TGF-β and different herbal compounds
and observed a synergistic effect of TGF-β and Baicalin with
respect to Foxp3 mRNA expression (data not shown).
Baicalin up-regulates Foxp3 expression in HEK 293 T cells
After transfection with pZIGF, HEK 293 Tcells were treated
with Baicalin, which resulted in both dose- and time-
dependent increases in the expression of Foxp3 mRNA
(Figure 2A and B). Because TGF-β can induce the expres-
sion of Foxp3 and inflammatory cytokines such as IL-6 may
inhibit its expression [24], we studied Baicalin’s effects on
Foxp3 expression in the presence of TGF-β and IL-6. As
expected, the addition of TGF-β and IL-6 to transfected
cells inhibited Foxp3 mRNA expression, whereas thexp3 mRNA levels in transfected HEK 293 T cells are shown
another 24 h. The dose-dependent induction of Foxp3 mRNA
the vector control (expression level of the vector control was set as
of cells was treated with 20 μM Baicalin. The time-dependent
± SD (expression level at 0 h was set as 1.0). (C) Transfected HEK
e of Baicalin for another 24 h. Foxp3 mRNA was examined by RT-PCR.
icalin for 24 h, and IL-6R mRNA levels were examined by RT-PCR.
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sion (Figure 2C) by countering the activity of IL-6. Further-
more, our data showed that treating transfected HEK 293 T
cells with IL-6 could induce the expression of IL-6R mRNA
and that treatment with Baicalin could inhibit IL-6 receptor
mRNA expression (Figure 2D).Baicalin promotes Foxp3 expression in CD4+CD25- T cells
To determine the effects of Baicalin on endogenous
Foxp3 expression, CD4+CD25- T cells from wild-type B6
mice were sorted by FACS and activated with anti-CD3
and anti-CD28 antibodies in the presence of Baicalin.
Our data showed that Baicalin could induce the differen-
tiation of these Treg cells in a dose-dependent manner
(Figure 3A). Confocal microscopy of the activated cells
revealed nuclear expression levels of Foxp3 protein in
CD4+CD25-T cells after a 3-day treatment with Baicalin
(Figure 3B, C). Further study showed that in the presence
of Baicalin CD4+CD25+T cells have stronger inhibition on
the proliferation of effector T cells (Figure 3D). These data
demonstrate that Baicalin could promote nuclear Foxp3Figure 3 Baicalin up-regulates Foxp3 expression in CD4+CD25- T cells
with indicated doses of Baicalin for 3 days. Foxp3 expression in the gate of
from B6 mice were cultured in the presence or absence of Baicalin for 3 da
in the CD4+ T cells. The scale bar represents 4 μm. (C) Five independent ce
from three independent experiments. (D) CFSE labeled CD4+CD25- T cells w
or absence of Baicalin for 5 days, the proliferation of cells was determinedexpression, induce CD4+CD25+ Foxp3+ Treg cell differen-
tion and strengthen the regulatory function.Discussion
Baicalin, an active ingredient originally isolated from the
root of the Chinese herb Huangqin (Scutellaria baicalensis
Georgi), has been used as an anti-inflammatory drug in
traditional Chinese medicine practices [25,26]. Previous
studies have investigated Baicalin’s mechanisms of action,
revealing that Baicalin could suppress the production of
inflammatory mediators such as IL-6 [25], bind to a variety
of chemokines to limit their biological functions [27], and
prevent leukocyte adhesion [28]. In addition, we have pre-
viously shown that Baicalin inhibited Th17 cell differenti-
ation both in vitro and in vivo, Baicalin could restore IL-6-
mediated inhibition of Foxp3 [29]. But whether Baicalin
could promote Foxp3 expression in the absence of TGF-β
is not clear, whether Treg cells generated in the presence of
Baicalin maintain regulatory activity is not known.
In the current study, we found that Baicalin up-regulated
both exogenous and endogenous Foxp3 expression and. (A) FACS-sorted CD4+CD25- T cells from B6 mice were stimulated
CD4+ T cells was determined by flow cytometry. (B) CD4+CD25- T cells
ys. Using confocal microscopy, nuclear Foxp3 expression was detected
lls were selected randomly from each sample, and shown are results
ere co-cultured with CD4+CD25+ T cells at a 2:1 ration in the presence
by flow cytometry.
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Foxp3 expression, which confirmed previous findings that
Foxp3 expression was restored after its initial suppression
of specific pro-inflammatory cytokines [24]. TGF-β induces
the differentiation of Treg cells, whereas IL-6 inhibits TGF-
β-induced generation of Treg cells [17], and IL-6 blockade
by treatment with an anti-IL-6R monoclonal antibody could
promote Treg cell differentiation [30]. Our data showed that
Baicalin could inhibit IL-6R mRNA expression, which
implied that Baicalin could restore IL-6-IL-6R-mediated in-
hibition of Foxp3 expression during Treg cell differentiation.
We further determined that Baicalin could directly up-
regulate the expression of Foxp3 in transfected HEK 293 T
cells and cultured T lymphocytes in the absence of TGF-β.
In addition, we confirmed that Baicalin induced the nuclear
expression of Foxp3 and promote Treg cell differentiation
in vitro. T cells stimulated with Baicalin showed more
powerful inhibition on the proliferation of effector T cells,
which indicated the expression of Foxp3 is correlated to the
Treg cell activity. Although our data showed that Baicalin
could directly promote Foxp3 expression in T cells, further
investigations should explore the possible mechanisms,
such as epigenetic regulation.
Autoimmune responses and homeostasis are maintained
by a fine balance between effector T and Treg cell activities.
In patients with autoimmune diseases, the proliferation of
effector T cells is directly related to the depletion and/or
dysfunction of Treg cells [31]. During an immune response,
feedback regulators initiate and activate effector cell activ-
ities, so the exclusive inhibition of specific effector T cells
may not effectively control the response. Therefore, for the
treatment of autoimmune diseases, therapeutic agents that
can regulate the relationship between effector T cells and
Treg cells rather than those that only regulate effector T cells
are of great clinical interest [31]. Our data showed that
Baicalin could promote Treg cell differentiation and up-
regulate the regulatory function of Treg cells in vitro, which
imply that Baicalin might be used for the treatment of auto-
immune diseases. Whereas further study should be done to
elevate the role of Baicalin on the differentiation of Treg
cells in vivo.Conclusions
In this study, we demonstrated that Baicalin could en-
hance the expression of Foxp3, potentially promoting Treg
cell differentiation and activity in vitro. Specifically, the
Foxp3-mediated induction of Treg cells may control auto-
immune diseases by eliminating inflammation caused by
effector T cells; thus Baicalin might serve as a promising
natural immunosuppressive compound for the treatment
of autoimmune diseases.
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